Talacotuzumab - Janssen Biotech

Drug Profile

Talacotuzumab - Janssen Biotech

Alternative Names: CSL 362AML; CSL-362; JNJ 473; JNJ 56022473; TAL

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL
  • Developer CSL; Janssen Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin-3-receptor-alpha-subunit-antagonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes
  • Preclinical Systemic lupus erythematosus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 14 Jun 2018 Efficacy and adverse events data from the phase II SAMBA trial in Acute myeloid leukaemia and Myelodysplastic syndromes presented at the 23rd Congress of the European Haematology Association (EHA-2018)
  • 12 Feb 2018 Janssen Research and Development completes a phase III trial in Acute myeloid leukaemia (Combination therapy, In the elderly, Second-line therapy or greater) in USA, Belgium, Spain, France, Italy, Australia, Germany, Israel, Russia, United Kingdom, Taiwan, Poland, Sweden, South Korea and Turkey (IV) (NCT02472145)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top